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INTRODUCTION 
 
Telomeres are essential chromosomal elements, which 
ensure proper replication and protection of chromosome 
ends. Human telomeres are constituted by 2-12 kb of 
double-stranded TTAGGG repeats and present a single-
stranded overhang of about 150 nucleotides. Telomeres 
prevent an inappropriate DNA damage response by 
recruiting a six-protein complex called shelterin, which 
is able to inhibit the induction of ATM and ATR 
responses [1]. They are also part of a feedback loop that 
ultimately regulates the ability of telomerase to add 
TTAGGG repeats preferentially to short telomeres [2]. 
Both of these activities require binding of POT1, one of 
the shelterin components, to the telomeric overhang [3]. 
 
The assembly of shelterin on the telomere is initiated by 
TRF1 and TRF2, which bind double stranded TTAGGG 
repeats directly through a MYB-type DNA binding 
domain.  They in turn recruit RAP1, TIN2, TPP1 and  
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POT1 [1]. TIN2 has the ability to interact with both 
TRF1 and TRF2 simultaneously, and additionally 
recruits TPP1/POT1 to the complex. The TPP1/POT1 
heterodimer is believed to have a dual role in the 
regulation of telomerase. POT1 itself is able to prevent 
or limit telomere elongation through its DNA binding 
activity [4], and TPP1 possesses a recruitment domain 
for telomerase providing a link between the enzyme and 
the chromosome’s end [5]. It is with two N-terminal OB 
folds that POT1 binds the telomeric overhang, with high 
affinity and sequence specificity [6, 7].  
 
Extensive analysis of the shelterin complex by mass 
spectrometry and proteomics, performed by a number of 
laboratories [3, 8-10] has led to the discovery of 
shelterin as a stable complex of six proteins, and in 
some cases, has identified components transiently 
associated with telomeres (eg. the MRE11 complex 
[11]). However, some other components known to 
impact on telomere function, including telomerase 
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itself, have been difficult to detect at telomeres by 
biochemical methods. These may not be associated with 
telomeres throughout the cell cycle, and are recruited 
through poorly understood regulatory events. For 
instance, the WRN helicase, mutated in the aging 
disease Werner syndrome, was shown to associate with 
telomeres in S-phase and to participate in lagging strand 
DNA synthesis [12]. Thus, some activities, although 
only transiently associated with shelterin, may be 
important to mediate its role in telomere function. The 
currently established shelterin-associated components 
are recruited through structurally related domains in 
TRF1 and TRF2 by recognition of F/Y-X-L-X-P 
docking sites [13]. Another important interaction at the 
telomere involves the OB fold of TPP1, proposed to be 
important for the recruitment of telomerase at 
chromosome ends [5].  
 
POT1 regulates telomere length through its overhang 
binding activity and mediates telomere protection 
through inhibition of the checkpoint kinase ATR [1]. 
POT1 is composed of two functional domains. The first 
domain lies in the C terminus, and mediates the 
recruitment of POT1 to telomeres through an interaction 
with TPP1 [14, 15]. The second domain is the N-
terminal DNA binding domain constituted by two OB 
folds, responsible for binding the telomeric overhang 
with high affinity and sequence specificity [7]. The two 
POT1 OB folds span the first 299 amino acids of the 
protein [7]. It is through the binding of the telomeric 
overhang that POT1 exerts its biological function at 
telomeres. 
 
The DNA binding activity of POT1 was shown, in the 
mouse conditional knock out system, to mediate 
repression of the ATR kinase [16, 17], itself an 
important component of the DNA damage response. 
This response, which is detected upon the removal of 
POT1 in mouse cells, results in the convergence and 
accumulation of DNA damage proteins at telomeres, 
which are in this case “sensed” as damaged DNA. For 
instance, DNA damage proteins p53BP1, γH2AX [18], 
and MDC1 [19] can be detected as foci co-localizing 
with telomeres. Ultimately, telomere deprotection can 
lead to extensive end-to-end telomere fusions, a 
catastrophic cellular event. The initial convergence of 
proteins involved in the DNA damage response at 
telomeres leads to the formation of TIFs, (telomere 
dysfunction-induced foci). 
 
Another important role for POT1 is the cis-inhibition of 
telomerase. Depletion of POT1 by siRNA leads to 
elongation of telomeres in telomerase-positive cells 
[20], placing POT1 in a cis-inhibiting pathway of 
inhibition of telomerase as a part of the shelterin 
complex. The engagement of POT1 with the overhang 
is essential for this inhibitory role, because expression 
of a N-terminal truncation of the DNA binding domain 
leads to extensive telomere elongation [4, 21].  
 
In vitro systems have demonstrated a positive role for 
POT1 and the POT1-TPP1 heterodimer in telomerase 
activity on a model telomere seed [22]. POT1 by itself 
can lead to increased telomerase recruitment depending 
on the distance between the binding site and the 3’end 
of the DNA. More recently, the POT1-TPP1 dimer has 
been shown to increase repeat addition processivity of 
the enzyme through a domain in TPP1 [23]. TPP1 itself 
has been proposed to directly recruit telomerase to 
telomeres through an OB fold present in the molecule 
[5]. Therefore, POT1-TPP1 has a dual role in 
telomerase regulation: a positive role through 
recruitment and enzymatic regulation of the enzyme, 
and a negative role through overhang binding activity. 
These complex activities of POT1 could be regulated in 
vivo by yet unknown factors. 
 
Since the DNA binding domain of POT1 is essential for 
both telomere length control and the inhibition of the 
DNA damage response at telomeres, protein 
associations with this domain are of great interest to 
explore. For instance, the roles of POT1 in inhibiting 
telomerase and the ATR kinase could be mediated by a 
factor that could either modulate the overhang binding 
of POT1, or act as a mediator molecule once POT1 has 
engaged on the DNA. 
 
In this study, we sought to isolate POT1-associated 
factors that interact with the DNA binding domain of 
the molecule, therefore expected to play a role in the 
function of POT1 and not its recruitment. We employed 
the yeast two-hybrid system to discover potential novel 
shelterin-associated proteins. To that end, we targeted 
the screen for candidates binding to the N-terminal 
domain of POT1, containing the two DNA binding OB 
folds. We report on the finding that the LIM domain 
proteins TRIP6 can interact with the POT1 DNA 
binding domain by two-hybrid, an interaction that we 
confirmed in human cells. TRIP6, initially identified as 
a Thyroid Receptor Interacting Protein, met the criterion 
of binding specifically the N-terminus of POT1 by yeast 
two-hybrid analysis, and can be detected in a complex 
with POT1 and other shelterin components in human 
cells. TRIP6 was previously implicated in cytoskeletal 
rearrangements and in transcriptional control [24]. LIM 
domains are known protein interaction domains that 
present distinctive loops defined by interactions 
between Cys and His residues coordinating a Zn ion, 
and define a family of proteins subdivided in specifics 
groups (reviewed in [25]). Our data is compatible with 
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TRIP6 being transiently associated with telomeres, an 
association which is readily detected by chromatin 
immunoprecipitation. We report that the closely related 
LIM protein LPP was also found in a complex with 
shelterin components. We found that single depletion of 
TRIP6 or LPP leads to TIF formation detected by 
accumulation of p53BP1 at telomeres. Based on our 
results, we propose that TRIP6 and LPP are both 
important for telomere protection. 
 
RESULTS 
 
Choice of the POT1 bait and yeast two-hybrid screen  
 
In order to specifically screen for proteins that associate 
with the DNA binding domain of POT1, we constructed 
an allele predicted to contain the full OB fold necessary 
for DNA binding, but with a truncated TPP1 interacting 
domain. The locations of these domains have been 
extensively described and mapped [7, 15, 17]. The 
POT1 allele we constructed, termed POT1∆C, contains 
the first 379 amino acids of the protein, with a full 
DNA-binding domain as described in [7], with an 
additional 79 amino acids, but not the TPP1-binding 
domain, located in the C-terminal region [15]. 
Therefore, POT1∆C should be unable to quantitatively 
associate with telomeres but retain full DNA binding 
activity. Introduction of a MYC-tagged version of 
POT1∆C by retroviral transduction in HTC75 cells 
showed that this allele was expressed at significantly 
lower levels than full-length POT1 (1A, left). This was 
also observed in the context of a fusion with GFP, 
where GFP-POT1∆C showed lower levels than the 
GFP-POT1 wild-type fusion (Figure 1A, right). Despite 
low levels of expression, the GFP-tagged NLS-
POT1∆C construct allowed us to assess the intranuclear 
localization of the protein. As predicted, and unlike full-
length GFP-POT1, GFP-POT1∆C failed to accumulate 
to telomeres, but instead showed a diffuse nuclear 
pattern (Figure 1C). A GST-POT1∆C construct was 
made that allowed us to perform in vitro DNA binding 
assays. We found that the binding affinity of GST-
POT1∆C was indistinguishable from that of the full-
length protein (Figure1B). Therefore, the POT1∆C 
allele represents a segment of POT1 with a full DNA 
binding domain, suitable for expression in yeast as a 
two-hybrid bait. The screen was expected to yield 
clones that associate with the DNA binding domain of 
POT1, and to exclude TPP1, which interacts with the C-
terminus of the molecule [15]. 
 
The yeast two-hybrid screen was performed with LexA-
POT1∆C as a bait, in the L40 yeast strain, with the 
LacZ and HIS3 genes as reporters. After initial scre-
ening of 2x106  transformants and subsequent retesting, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 plasmids were recovered that conferred robust His+ 
and LacZ+ phenotypes upon re-transformation (Figure 
2A). During the retests, plasmids containing TRF1-
GAD, TRF2-GAD (Figure 2A, 2B) and RAP1-GAD 
Figure  1. Localization  and  DNA  binding  activity  of  the
POT1
∆C 
allele. (A) Expression  levels  of  MYC‐or  GFP‐tagged
alleles in HTC75 cells. The full‐length (FL, 71kD), POT1∆OB (∆OB,
MW  57kD)  and  POT1∆C(∆C,  MW  43kD)  are  shown  along  a
vector‐only control. Blots probed with the 9E10 (anti‐MYC) (left)
or  978  (anti‐POT1)  antibodies  (right)  are  shown.  (B)  Gel  shift
assay for GST‐POT1 and GST‐POT1∆C. A 32P‐labelled oligonucleo‐
tide  containing  the  POT1 minimal  binding  site  was  incubated
with the amounts of GST fusion protein shown on top. The free
probe  is  visible  at  the  bottom  of  the  autoradiogram.  (C)
Intranuclear localization of GFP‐NLS‐POT1 and GFP‐NLS‐POT1∆C.
The GFP‐tagged  protein  is  detected  in  the  FITC  channel  (left),
and  telomeres  are  stained  with  an  anti‐TRF1  antibody  (371,
middle panels). The overlay is shown in the right panels. 
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(not shown), all fusions that were analyzed in separate 
studies in the L40 strain [26] [27], were also tested 
against the LexA-POT1∆C bait and showed no 
activation, demonstrating the specificity of the 
interaction for the bait. All three recovered clones 
corresponded to the 3’ half of the same cDNA, 
containing the three C-terminal LIM domains of TRIP6 
in fusion with the GAL4 activation domain at amino 
acid 218. Tests performed in yeast confirmed that the 
clones interacted with full-length POT1 (Figure 2B), 
showing that the interaction detected in yeast was not an 
artifact of the truncation of the protein. The activation 
of LacZ was evident with both POT1∆C and full length 
POT1, although in the latter case some background 
activation of the promoter occurred without the prey 
(Figure 2B). We also tested the library clone obtained 
against other LexA fusions such as LexA-TRF1 (Figure 
2B), showing that the TRIP6 fusion had specificity for 
the POT1 bait. Altogether, the results from the two-hyb- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rid screen argue for an interaction between the N-
terminal domain of POT1 and the C-terminal LIM 
domains of TRIP6. A POT1∆OB fused to LexA 
construct was also tested against the TRIP6 fragment, in 
order to ask whether the interaction was lost when the 
first OB fold is absent. In this case, the high LacZ+ and 
His+ background caused by POT1∆OB alone precluded 
the analysis. TRIP6 was isolated previously as one of 
the thyroid receptor interacting molecules and was later 
characterized as binding to adhesion plaques. A role for 
organizing the actin cytoskeleton at adhesion plaques 
has been established [28], and nuclear roles for the 
protein have been described [29, 30]. The molecule has 
a molecular weight of 60kD and can be divided into two 
roughly equivalent regions: an N-terminal half, 
containing a nuclear export sequence, referred to as the 
pre-LIM domain, and a C-terminal half with three 
predicted LIM domains. It is the latter region of TRIP6 
which was isolated in the screen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The LIM domains of TRIP6 interact with POT1∆C by yeast two‐hybrid. (A) Top: His phenotypes of the B40 strain
carrying the pLexA‐POT1∆C bait plasmid and the plasmids shown on the right side,  including the b12 positive clone and another
recovered clone, c3, which proved negative upon retransformation. Bottom: Patch LacZ assay of the same strains, showing that the
b12 clone activates the LacZ reporter gene as well. (B) Liquid β‐Gal assays using the B40 yeast strain and the bait plasmids shown at
the bottom, with the GAD vector or GAD‐b2 clone. The b2 clone activates LacZ with LexA‐POT1 or LexA‐POT1∆C, but not with LexA‐
TRF1. The standard deviations were calculated on three independent yeast colonies, each assayed three times. 
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Cloning and expression of the full-length human 
TRIP6 cDNA 
 
The full-length TRIP6 cDNA was obtained as an EST 
and cloned into a retroviral mammalian expression 
vector (pLPC) in fusion with a FLAG or MYC epitope 
tag, in order to express the tagged full-length cDNA in 
human cells. We sought first to confirm the interaction 
between POT1 and TRIP6 detected in yeast. Transient 
co-transfections in 293T cells with full-length POT1, 
POT1∆C or POT1∆OB were performed to ask whether 
MYC-POT1 could coimmunoprecipitate specifically 
with FLAG-TRIP6. We found that TRIP6 could pull 
down full-length POT1 (Figure3A). In addition, co-
transfection of TRIP6 resulted in the stabilization of 
POT1. Both these observations suggest an interaction 
between full-length TRIP6 and POT1. No interaction or 
stabilization was detected with POT1∆OB (Figure3B), 
suggesting, in conformity with the setup of the yeast 
two-hybrid screen, that the N-terminal OB folds are 
important for the POT1-TRIP6 interaction. It is 
possible, although not demonstrated here, that the first 
OB fold of POT1, which is missing in POT1∆OB, is 
necessary for the interaction. We also used MYC-
POT1∆C in this assay. Owing to the low expression of 
the protein (see above), we could not detect an 
association with TRIP6 in this case. However, a 
stabilization of MYC-POT1∆C upon co-transfection 
with FLAG-TRIP6 was observed (not shown), 
compatible with an interaction between the two 
proteins. 
 
A MYC-tagged TRIP6 cDNA was stably introduced by 
retroviral transduction into HTC75 cells, in order to 
further the co-immunoprecipitation analysis and to 
study the localization of the protein by 
immunofluorescence. In MYC-TRIP6 expressing cells, 
a weak but reproducible signal was detected after 
immunoprecipitation with two independent anti-POT1 
sera (Figure 4A). This confirmed that the interaction 
detected by yeast two hybrid and transient transfection 
was detectable in stably expressing cells. We then 
explored whether TRIP6 could be pulled down with 
antibodies against other shelterin components. A very 
robust precipitation of TRIP6 was observed with an 
anti¬TRF2 antibody (Figure 4A). TRIP6 could also be 
pulled down with TIN2 antibodies (Figure 4A). Because 
TRIP6 could be pulled down by antibodies to several 
shelterin components, our results argue for an 
association between TRIP6 and the whole complex. We 
cannot rule out a direct interaction between TRIP6 and 
other shelterin components, such as TRF2, that are not 
detected by the yeast two-hybrid tests. The cellular 
localization of TRIP6 in our established cell lines was 
seen as mostly cytosolic staining, as previously 
described by others (SS and DL, unpublished, and [30]). 
We found no evidence for telomeric localization by 
immunofluorescence. We reasoned that accumulating 
TRIP6 in the nucleus might increase the signal detected 
in the co-immunoprecipitation experiments. To test this, 
we generated an allele of TRIP6 with an inactivated 
NES (the allele described in [30]), named TRIP6-NES . 
We confirmed by immunofluorescence that this mutant 
allele accumulated in the nucleus. No difference was 
observed in the coprecipitation between POT1 or TRF2 
and wild-type or TRIP6-NES (not shown). It is possible 
that the interaction between TRIP6 and shelterin is 
highly regulated and not driven by high nuclear 
amounts of the protein. 
 
LPP, closely related to TRIP6, also interacts with 
shelterin  
 
In our analysis of TRIP6, we noted that the human 
genome encodes a highly related protein called LPP, 
which, as TRIP6, is part of the Zyxin family. The 
Figure  3.  POT1  interacts  with  TRIP6  in  transient 
transfections. (A) IP‐Western  blots  on  lysates  made  from 
transiently  transfected  293T  cells,  to  detect  co‐
immunoprecipitation  of  the  transfected  proteins.  MYC‐POT1 
was  co¬transfected with  FLAG‐TRIP6  or with  the  FLAG  vector, 
and  the  lysates were  used  for  immunoprecipitations with  the 
9E10 (anti‐MYC) or M2 (anti‐FLAG) antibodies, as shown on top. 
A  Total  fraction  (TOT)  and  beads  only  control  (B)  were  run
alongside. The blot was probed with the 9E10 antibody, and the 
position  of  MYC‐POT1  is  indicated  by  the  arrow.  The 
immunoprecipitated MYC¬POT1 by the FLAG antibody is shown 
with  the  black  triangle.  (B)  Same  as  A,  except  that  MYC‐
POT1∆OB is used in the co‐transfection. 
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homology in the C-terminal LIM domains between 
TRIP6 and LPP is very high: the sequence identity 
between the two in the first LIM domain is about 60%, 
and 77% and 75% for the second and third LIM 
domains respectively [31]. The high homology between 
the C-termini of TRIP6 and LPP prompted us to 
investigate whether LPP also associated with shelterin. 
Although the degree of identity is lower in the N-
terminal third of the protein (around 35%), the overall 
domain structure is identical between LPP and TRIP6, 
with, notably, a nuclear export sequence arguing for 
active shuttling of LPP between cytoplasm and nucleus. 
Based on the degree of homology and domain structure 
of the two molecules, it is possible that TRIP6 and LPP 
share an ability to interact with shelterin. The full-
length LPP cDNA was cloned into pLPC-MYC and 
stably expressing cell lines were obtained in HTC75. By 
IP-Western, MYC-LPP was found to co-precipitate with 
POT1, TRF2, TRF1 or TIN2 antibodies (Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, LPP could associate with shelterin as well. 
This shared ability with TRIP6 to be in a complex with 
shelterin could be mediated by the highly similar C-
terminal LIM domains, although the interaction 
domains in TRIP6 and LPP remain to be defined. 
 
TRIP6 and LPP can be detected at telomeres by 
chromatin immunoprecipitation 
 
 Immunofluorescence analysis of TRIP6 or LPP 
localization yielded results in accordance with a 
previously published report [30]: the pattern displayed 
cytoplasmic staining compatible with a much higher 
concentration of TRIP6 and LPP in the cytoplasm than 
in the nucleus. We confirmed the published observation 
that TRIP6 or LPP could accumulate in the nucleus 
upon treatment with Leptomycin B supporting the 
notion that they both actively shuttle between nucleus 
and cytoplasm (SS and DL, unpublished). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. TRIP6 and LPP co‐immunoprecipitate with several shelterin components. (A) IP‐Western blots
on lysates made from HTC75 cells obtained through retroviral transduction, stably expressing MYC‐TRIP6 (50kD)
(the vector only control is shown on the left). The lysates were used for immunoprecipitations with the antibodies
listed on  top, and analyzed  for  the amounts of MYC‐TRIP6 by Western blot with  the 9E10 antibody. The Total
fraction  was  ran  alongside  as  indicated.  The  POT1  sera  were  the  anti‐epitope  #4955  (left  panel),  and  the
anti¬baculovirus POT1 #1048 (right panel). (B) Same as A, as with a MYC‐LPP (66kD) expressing HTC75 cells. 
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In order to address whether TRIP6 or LPP associate 
with shelterin at telomeres, we turned to the chromatin 
immunoprecipitation (ChIP) technique. This technique 
has been extensively used to study the presence of 
shelterin components or other proteins on telomeric 
DNA. Anti-peptide rabbit sera against TRIP6 or LPP 
were used for this analysis, which were both raised 
against epitopes in the N-terminus which were 
significantly divergent between the two proteins. We 
confirmed that the TRIP6 and LPP sera were competent 
for immunoprecipitations and not crossreacting (Figure 
S2). In asynchronous HTC75 cells, TRIP6 was found to 
associate with telomeres with a yield of about 5% of 
total TTAGGG DNA (Figure 5A,5B), about half the 
yield seen for POT1 in this assay and comparable with 
the yield obtained for TPP1. TRF1 antibodies, used as a 
control here, pulled down 20% of total telomeric 
sequences, in accordance with previously published 
results [4].  LPP could also be detected at  telomeres  by  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ChIP (Figure 5A). The yield for LPP was 3.5% of total 
DNA, in the same range as TRIP6. The yields for Alu 
sequences, used her as internal control sequences, was 
between 0.5 and 1% for all samples. These results show 
that the interactions between TRIP6 or LPP and 
shelterin are taking place at the telomere and likely 
reflect a role for these LIM-domain proteins in telomere 
function. Thus, both TRIP6 and LPP are found at 
telomeres in asynchronously growing HTC75 cells. 
 
We also probed the telomeric association of TRIP6 and 
LPP by ChIP in cells expressing POT1∆OB . These 
cells have highly elongated telomeres, concomitant with 
a lower expression of endogenous full-length POT1 [4]. 
We found that TRIP6 or LPP show a yield similar to 
that observed in non-expressing HTC75 cells (ca 5%) 
(Figure 5A, 5B), which results in a stronger signal on 
the dot-blot (Figure 5A) due to the significantly longer 
telomeres in POT1∆OB cells.  Such a pattern is observed 
Figure 5. TRIP6 and  LPP are detected at  telomeres by ChIP.  (A) Chromatin  immunoprecipitations with
fixed  lysates  prepared  from  HTC75  cell  lines  indicated  on  the  left.  The  antibodies  used  are  listed  on  top
(I=Immune, PI=PreImmune), and the Total DNA  fraction  is on the right side of each blot as  indicated. Extracted
DNA samples were dot‐blotted on Nitrocellulose, and probed with a TTAGGG probe (top), or with an Alu probe
(bottom) as a control. The yields calculated for the samples probed with Alu were all below 0.5%. (B) Histogram of
the values for the yields as % of total DNA of the samples shown in A. 
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for other telomeric or telomere-associated proteins such 
as TRF1 (see Figure 5A), POT1, RAP1 or MRE11, and 
is evidence for association with the overall telomeric 
chromatin [4]. Therefore, it appears that TRIP6 and LPP 
associate with shelterin along the whole telomere. Also, 
the strong depletion of full length, endogenous POT1 in 
POT1∆OB cells [4] does not lead to a disappearance of 
TRIP6 or LPP from telomeres, suggesting that the OB 
folds of POT1 are not involved in recruiting TRIP6 or 
LPP to telomeres, which would then occur through 
other events or interactions to be defined. Thus, the 
interaction between the LIM domains of TRIP6 and the 
N-terminus of POT1 is not expected to mediate the 
recruitment of TRIP6, but rather to be relevant to the 
function of the protein. Whether the same holds true for 
LPP remains to be determined, but the high homology 
between the LIM domains of LPP and TRIP6 suggest 
that they both are able to interact with the POT1 N-
terminus. The modalities of recruitment of TRIP6 and 
LPP to telomeres are interesting questions to pursue. 
 
TRIP6 and LPP are involved in telomere protection 
  
To analyze the possible roles of TRIP6 and LPP in 
telomere function we first examined telomere length in 
HTC75 cells over 60 population doublings in cells 
overexpressing either TRIP6 or LPP. The impact of 
shelterin components depletion or overexpression is 
normally detected during this span, but no effect was 
observed for TRIP6 or LPP (data not shown). We then 
turned to the analysis of TRIP6 or LPP siRNA depletion 
on telomere protection in HTC75 cells. 
 
We analyzed the possible short-term effects (48hr post 
transfection) of TRIP6 or LPP depletion on the 
induction of a DNA damage response at telomere. Such 
a response can be monitored by the induction of 
p53BP1 foci that partially co-localize with telomeres, 
indicative of telomere de-protection [18,32]. For siRNA 
of TRIP6 or LPP, we used targets sites that led to partial 
depletion of exogenous MYC-TRIP6 or MYC¬LPP as 
observed by Western blot (Figure S1). The depletion of 
TRIP6 led to a significant increase of p53BP1 foci in 
the nuclei, suggestive of an induction of a DNA damage 
response a numerous sites in the genome. The number 
of p53BP1 nuclear foci increased from an average of 1 
to 2.65 per nucleus, including untransfected cells which 
tend to lower the number in this case. In particular, we 
observed the induction of telomere dysfunction induced 
foci (TIFs), as observed by the formation of p53BP1 
foci that co-localized with TRF2 (Figure 6). Upon 
depletion of TRIP6, 40% of the nuclei showed 3 or 
more p53BP1 foci co-localizing with TRF2, indicating 
that some of these foci represented a DNA damage 
response at telomeres. This value represented a 2.7-fold 
increase over background, detected in the GFP siRNA 
control. 
 
We observed similar results with the siRNA depletion 
of LPP. In this case also, an overall increase of p53BP1 
was evident, from 1 to 1.8 foci per nucleus, arguing for 
a role in general repression of a DNA damage response 
in these cells. The degree of TIF formation was similar, 
but slightly lower, to that observed with TRIP6, with 
32% of the cells showing 3 or more foci co-localizing 
with TRF2, a two-fold increase over background. Since 
depletion of either TRIP6 or LPP alone led to a DNA 
damage response at telomeres, we conclude that both 
are necessary to fully protect telomeres, possibly by 
cooperating with POT1. 
 
DISCUSSION 
 
In this study, we describe a novel association between 
shelterin and LIM domain proteins at telomeres. These 
are the LIM-domain proteins TRIP6 and LPP, two 
related molecules of the Zyxin family [25]. We first 
identified TRIP6 in a two-hybrid screen for proteins that 
associate with the DNA binding domain of POT1. 
Binding to POT1 and the shelterin complex could have 
two significant consequences: the recruitment of the 
protein to telomeres, and a role in telomere function. 
Given that the DNA binding domain of POT1 mediates 
the function of the protein in protection and length 
regulation [1], and that TRIP6 and LPP recruitment are 
not affected by high expression of POT1∆OB, we argue 
that the interaction between POT1 and TRIP6 detected 
in yeast relates to function and not recruitment. It 
remains to be determined how and when TRIP6 and 
LPP are recruited to telomeres.  
 
The LIM superfamily of proteins contains at least 50 
members in the human proteome and is subdivided into 
seven families, all made of proteins with predicted LIM 
domains in various arrangements [25]. TRIP6 is part of 
the Zyxin family, along with other members such as 
LPP or Ajuba, characterized by the presence of three 
LIM domains at the C-terminus of the molecule. 
However, intriguingly, these molecules possess a 
nuclear export sequence, which accounts for their active 
shuttling between the nucleus and the cytoplasm. A 
nuclear role for TRIP6 as a transcription factor has 
been described [29, 30], arguing for an important role 
for this molecule in addition to that performed in the 
cytoplasm.  
 
TRIP6 and LPP are not detected at telomeres by 
immunofluorescence, and, instead, show a cytoplasmic 
localization pattern seemingly at odds with a role in the 
nucleus and at telomeres (DL and SS, unpublished, and 
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[30]). However, they are known to shuttle actively 
between the cytoplasm and the nucleus, in a manner 
dependent on the NES present in the N-terminal half of 
the molecule [30]. The telomeric association we detect 
is therefore probably not representative of the majority 
of the cells in the population, but rather occurs in a 
minority of the cells experiencing high TRIP6/LPP nuc- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
lear concentration. Although this remains to be 
established, it would be interesting to investigate an 
accumulation of TRIP6 and LPP at telomeres during S-
phase, a period in the cell cycle with high demand for 
protective activities [33]. As such, TRIP6 and LPP 
would be active only transiently at telomeres, perhaps 
during DNA replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Depletion of TRIP6 or LPP leads to TIF formation. (A) Immunofluorescence showing
the intranuclear localization of p53BP1 in TRIP6¬depleted HTC75 cells (middle panels), LPP‐depleted
cells  (right  panels)  or  control  siRNA  (GFP,  left).  The  detected  fluorescence  (DAPI,  FITC  for  TRF2,
TRITC for p53BP1) is indicated on the left, and white triangle point to the co¬localized TRF2‐p53BP1
foci.  (B) Histogram of the values  for co‐localized p53BP1 and TRF2  foci  (left, greater than 3, right,
greater than 5 per nucleus) as a percent of the total nuclei counted. 100 nuclei were counted  for
each set, and the standard deviations were calculated on three separate experiments.  
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The roles of TRIP6 and LPP could impact on two main 
processes: either telomere protection or telomere length 
regulation through the control of telomerase. Our results 
suggest that TRIP6 and LPP both individually 
contribute to the protection of telomeres, in preventing 
the damage response otherwise elicited through 
activation of ATM or ATR pathways. An impact for 
TRIP6 or LPP on telomere length regulation has not 
been detected but is still under investigation. The high 
sequence similarity between TRIP6 and LPP likely 
accounts for their recruitment to telomeres, possibly 
through a common pathway, although our data argue 
that each individually is important for proper telomere 
protection. 
 
A nuclear role for LIM proteins, in particular in the 
Zyxin family, has been established previously. Like 
TRIP6, the protein Ajuba, has an NES as well as three 
C-terminal LIM domains. Ajuba was found to associate 
with kinetochores and to participate in the spindle 
assembly checkpoint [34]. Also, Ajuba was found to co-
repress transcription at RAREs through interactions 
with, among other factors, RARα. The mechanism of 
co¬repression was found to occur through recruitment 
of PMRT5, an Arginine methylase whose enzymatic 
activity was found to be essential in this process [35]. In 
this context, the LIM domains of Ajuba constitute a 
platform of interactions to mediate transcriptional 
repression through Arginine methylation. Interestingly, 
Ajuba shares the ability to interact with RARα with two 
other Zyxin family members, WTIP and LimD1, while 
TRIP6 and LPP are negative in this assay [35]. This 
observation parallels ours, in that more than one LIM 
protein can play a role in the same process. We find it 
tempting to speculate that TRIP6 and LPP bring similar 
activities to the telomeres, as Ajuba and WTIP do to 
RAREs, in recruiting for instance an Arginine 
methylase. Arginine methylation of TRF2, a shelterin 
component, has recently been implicated in telomere 
function, in particular in repressing premature sense-
cence in primary cells [36]. Therefore, there might be a 
subdivision in the Zyxin family, some members being 
involved in transcriptional repression, and others in 
telomere protection. Further work will determine 
whether the activities of TRIP6 and LPP at telomeres 
are important for the repression of the senescence path-
way under the control of shelterin, in particular TRF2. 
 
MATERIALS AND METHODS 
 
Two-hybrid screen/Isolation of TRIP6. A two-hybrid 
screen was carried out with the yeast reporter strain L40 
(Hollenberg et al., 1995; Bianchi et al., 1997), using the 
human POT1∆C C-terminal truncation (aa 1-379) fused 
to the LexA DNA binding domain as a bait. The L40 
strain bears the HIS3 and LacZ reporter genes under the 
control of the LexA DNA binding site. The libraries 
used were the HeLa S3 or the human testis matchmaker 
cDNA library (Clontech), containing random fusions to 
the GAL4 activation domain. The TRIP6 two-hybrid 
cDNA clones (aa positions) containing the three LIM 
domains of the molecule where isolated and re-
transformed into the L40 containing the bait to ensure 
that the His+ and LacZ+ phenotypes were due to the 
library plasmid. 
 
Two-hybrid assays. The two-hybrid tests shown in 
Figure 2 were performed also in the L40 strain with the 
LexA-TRIP6 full length cloned in pBTM116 (Bartel et 
al., 1993) by PCR of the TRIP6 EST (see below) and 
tested against a number of previously characterized and 
published fusions with the GAL4 activation domain: 
TRF1-GAD, TRF2-GAD, and POT1¬GAD, all cloned 
into the pACT2 vector (Clontech). The BGal liquid 
assays were performed as described in the Clontech 
Matchmaker protocol and three independent colonies 
were assayed for each plasmid combination, and the 
standard deviations reported are based on three separate 
experiments. 
 
Cell lines and antibodies. The HTC75 cell line is a 
HT1080 derivative described in [37]. The cells were 
grown in DMEM/10%BCS, and the retroviral 
transduction protocol was identical to that described in 
[38]. The antibodies against TRIP6 and LPP were 
generated against a peptide conjugated to KLH and used 
for immunization into rabbits, as per the protocol set by 
the manufacturer (BioSynthesis, Lewisville, TX). The 
peptides were: NH2-GCPKKFAPVVAPKPKYNPYKQ 
-OH for LPP, and GC-LNGGRGHASRRPDRQAYE-
OH for TRIP6. The TRF2 antibodies were the 647 
against the full-length protein made in Sf9 cells [11], or 
the anti-peptide 508 [39]; the TRF1 antibody was the 
anti-peptide 371 [37]; the POT1 antibodies were the 
1048 against the full-length protein made in Sf9 cells or 
the anti-peptide 978 [4]; and the Tin2 antibodies were 
the 864 made against the full-length protein in Sf9 cells 
[40]. The p53BP1 antibody was purchased from Novus 
(NB100-304). 
 
Plasmids. The TRIP6 and LPP cDNAs were purchased 
as full length clones from the EST collection maintained 
by the ATCC (TRIP6) or Invitrogen (LPP). The full 
length cDNAs were amplified by PCR using primers 
with appropriate cloning sites (5’ Bgl II and 3’ Xho I) 
and cloned into pLPC-MYC [38] to generate a MYC 
tagged version driven by the CMV promoter. The PCR 
oligonucleotides were: 5’ AGATCTTCGGGGCCCACC 
TGGCTGCCCCCG and 5’CTCGAGTCAGCAGTCAG 
TGGTGACGGTGGC for TRIP6, and 5’ AGATCTCA 
  
www.impactaging.com                   441                                             AGING, July 2010, Vol.2 No.7
CCCATCTTGGC and 5’ GAGTCTGAGCTAAAGGT 
CAGT for LPP. 
 
The POT1∆OB construct is described in [4], and the 
POT1∆C construct was cloned by PCR-cloning of 
amino acids 1-379 of POT1 into pLPC-MYC for 
expression into human cells, or pBTM116 to use as a 
bait for the two-hybrid screen. The POT1 and POT1∆C 
fusion with eGFP where performed using a vector 
constructed with the eGFP fragment from the pEGFP-
C1 vector (Clontech) subcloned into pBabe-Puro. An 
NLS was cloned as a BamHI fragment into the BglII 
site of the polylinker, and the full-length POT1 or 
POT1∆C fragments were cloned as BamHI-XhoI 
fragments downstream of the NLS, generating N-
terminally GFP-tagged protein fusions actively 
transported into the nucleus. 
 
RNA interference. HTC75 cells were maintained in 
DMEM (Invitrogen) supplemented with 1% penicillin 
and streptomycin and 10% fetal bovine serum (FBS). 
TRIP6, and LPP-specific siRNAs were synthesized by 
Dharmacon RNA Technologies. For TRIP6 RNAi, 
double-stranded siRNA were designed to target the 
following sequences: TRIP6(6.1)siRNA 5’-AGGAGGA 
GACUGUGAGAAUUU-3’ TRIP6(6.2)siRNA 5’-
CUGGAUAGGCUGACGAAGAUU-3’ LPPsiRNA(L.1) 
5’CUCAUAAUGUGAAAUAUGA¬3’ LPPsiRNA(L.2) 
5’GCCAUUCUAUGCUGUGGAA-3’ HTC75 cells 
were transfected using Lipofectamine (Invitrogen) 
according to the manufacturer’s instructions. Briefly, 
cells at a confluency of approximately 50-60% were 
plated in a 6-well plate 18-24 hr prior to transfection. 
Transfections were done one time within a 24 hr 
interval and cells were processed 48 hr after the first 
transfection. As a control, siRNA designed to target 
GFP (Dharmacon) was used. 
 
Immunofluorescence. Immunostaining for TRF2 and 
53BP1 proteins was performed on HTC75-Vector, 
MYC-TRIP6 or MYC-LPP cells plated onto glass 
coverslips. Cells were fixed with 2% formaldehyde in 
PBS (v/v) for 10 min at RT. Cells were permeabilized 
with 0.5% NP40 in PBS for 10 min at RT, washed two 
times in 1X PBS, and blocked with PBG for 30 minutes. 
Coverslips were then incubated with the mouse anti-
TRF2 antibody clone 4A794 (Millipore/Upstate 
Biotech) and a rabbit anti-p53BP1 antibody (Novus 
NB100-304A-1), both at a concentration of 1:1000 in 
PBG overnight. 
 
Cover slips were then rinsed three times with PBG 
solution and incubated with secondary TRITC-
conjugated goat anti-rabbit antibody or FITC-
conjugated donkey anti-mouse antibody (Jackson 
Immunoresearch) in PBG at a concentration of 1:1000 
for 45 min at RT. Cover slips were rinsed two times 
with PBG. Coverslips were then incubated with PBG 
and 4=,6=-diamidino-2-phenylindole (DAPI) at 100 
ng/ml to visualize the nuclei. Coverslips were mounted 
on to slides with embedding media. Images were 
collected with an Olympus BX61 fluorescence 
microscope using a 60X objective connected to a 
Hamamatsu ORCA-ER CCD camera, controlled by the 
SlideBook 5.1 image capture software. 
 
Chromatin immunoprecipitations. The chromatin im-
munoprecipitations were performed as described in [4]. 
 
E.coli GST-POT1 and bandshift assays. The purifica-
tion protocol is detailed in [41], and the bandshift assays 
were performed as described in [6]. 
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Figure S1. Depletion of TRIP6 or LPP by siRNA. Western blot of  lysates prepared  from MYC‐
TRIP6 or MYC‐LPP expressing cells transfected with the siRNA  indicated on top, with the anti‐MYC 
9E10 antibody as a probe.  The siRNA 6.2 was used for TRIP6 depletion, and P.1 for LPP depletion. 
Figure S2. The anti‐TRIP6 or LPP sera are proficient for immunoprecipitations. IP‐Western
blots  showing  that  the  rabbit  TRIP6  antibodies  (5023) or  LPP  antibodies  (6073,6074)  are  able  to
immunoprecipitate MYC‐TRIP6 or MYC‐LPP, with the preimmune sera (PI) as negative controls. The
TRIP6 sera did not precipitate LPP, and the LPP sera did not precipitate TRIP6. 
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